RBC Capital analyst Brian Abrahams maintained a Buy rating on Neurocrine today and set a price target of $156.00. The company’s shares opened today at $137.87.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Abrahams is a 3-star analyst with an average return of 2.1% and a 47.02% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Gilead Sciences, and PTC Therapeutics.
In addition to RBC Capital, Neurocrine also received a Buy from Bank of America Securities’s Tazeen Ahmad in a report issued on October 3. However, on September 22, BMO Capital reiterated a Hold rating on Neurocrine (NASDAQ: NBIX).
NBIX market cap is currently $13.83B and has a P/E ratio of 40.44.
Read More on NBIX:
Disclaimer & DisclosureReport an Issue
- Neurocrine presents new data from KINECT-HD2 study of ingrezza
- Neurocrine’s ingrezza shows efficacy in tardive dyskinesia
- Promising Phase 2 Results and Safety Profile of Osavampator Justify Buy Rating for Neurocrine Biosciences
- Neurocrine price target raised to $169 from $160 at Jefferies
- Neurocrine announces Phase 2 SAVITRI met primary efficacy endpoint
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Broadcom%20Inc%20HQ%20photo-by%20Sundry%20Photogrpahy%20via%20iStock.jpg)
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
